If you’ve tried two or more antidepressants and still don’t feel better, you’re not alone, and you’re not out of options. Treatment resistant depression (TRD) affects roughly 30% of people with major depressive disorder, and it’s one of the most frustrating situations a patient can face. You follow the rules, take your pills, wait the six to eight weeks, and nothing changes.
That’s exactly where TMS and ketamine therapy come in. These aren’t experimental fringe treatments anymore. They’re real, clinically backed options being offered at hospitals, clinics, and psychiatric centers across the world. But they work very differently, cost very differently, and aren’t right for the same people.
Let me break both down in plain language so you can actually have an informed conversation with your doctor.
First, What Does “Treatment-Resistant” Actually Mean?
Before diving in, let’s be clear on this term. Treatment resistant depression doesn’t mean your depression is impossible to treat. It simply means that at least two antidepressant medications, tried at the right dose, for the right amount of time, haven’t provided enough relief. That’s the clinical definition used in most research and medical guidelines worldwide.
It matters because both TMS and ketamine are specifically studied and approved for this population.
What Is TMS Therapy?
TMS stands for Transcranial Magnetic Stimulation. The name sounds intense, but the experience is surprisingly straightforward.
You sit in a chair, fully awake, no sedation needed, while a device placed near your head delivers short magnetic pulses to specific areas of your brain, primarily the prefrontal cortex. This is the region responsible for mood regulation, and in people with depression, it tends to be underactive.
Think of it like a gentle nudge to a part of the brain that’s been running too quietly.
A standard TMS course involves five sessions per week for four to six weeks, with each session lasting about 20 to 40 minutes. You can drive yourself home afterward and go about your normal day. There’s no anesthesia, no memory loss, and no systemic side effects like weight gain or sexual dysfunction that are so common with antidepressants.
The most common side effect is a mild headache or scalp discomfort during treatment, which usually fades within the first week.
Does TMS Actually Work?
Yes, and the evidence is solid. A landmark study published in Clinical Neurophysiology found that about 50 to 60% of patients with treatment resistant depression experience significant improvement with TMS, and roughly one third achieve full remission. The FDA cleared TMS for major depressive disorder back in 2008, and it has been studied extensively since then.
A newer form called Deep TMS (dTMS), which uses a different coil to reach deeper brain structures, received FDA clearance in 2020 and shows similar or slightly improved response rates in some studies.
One important thing to know, TMS results take time. Most people don’t feel a difference until two to three weeks into treatment. It’s a gradual lift, not an overnight switch.
What Is Ketamine Therapy?
Ketamine has been used as an anesthetic in hospitals for decades. But in the last ten years, researchers discovered something remarkable: at lower, carefully controlled doses, it acts as a rapid and powerful antidepressant, even in people who haven’t responded to anything else.
There are two main forms used in depression treatment today.
The first is IV ketamine infusion, which is the original research backed method. You receive a slow intravenous infusion of ketamine, typically over 40 minutes. in a clinical setting. A standard initial course involves six infusions spread over two to three weeks.
The second is esketamine (brand name Spravato), which is a nasal spray version of a ketamine related compound. It is FDA approved specifically for treatment resistant depression and is administered in a certified healthcare setting, where you are monitored for at least two hours afterward.
Does Ketamine Actually Work?
The results are genuinely impressive, especially the speed. Multiple studies, including research published in the American Journal of Psychiatry, show that 50 to 70% of patients experience significant depressive symptom reduction within 24 hours of their first infusion. For someone who has been severely depressed for months or years, that rapid response can be life changing.
It has also shown meaningful results in reducing suicidal ideation quickly, which is one reason it is increasingly used in acute psychiatric settings.
However, ketamine’s effects don’t always last. Many patients find that the relief begins to fade after one to three weeks without maintenance doses. This means ongoing infusions or nasal spray sessions are often necessary for sustained benefit, which adds up in both cost and time.
Side effects during infusion can include dissociation, dizziness, nausea, and elevated blood pressure. These typically resolve within a few hours. Long term risks of repeated ketamine use, including dependency potential, are still being studied, which is why proper patient selection and medical supervision matter enormously.
TMS vs. Ketamine (Side by Side)
When it comes to speed, ketamine wins clearly. Relief can arrive within hours. TMS works gradually over several weeks.
For lasting results, TMS tends to have a longer duration of benefit after a completed course, often six months to a year or more. Ketamine’s effects, while powerful, often require ongoing maintenance.
On the safety and side effect profile, TMS has the edge. It is non systemic, non-sedating, and carries no dependency risk. Ketamine requires close monitoring and is not appropriate for people with certain psychiatric or substance use histories.
A Note on Cost and Availability
Treatment costs vary significantly depending on where you live.
In the United States, a full TMS course typically runs $6,000 to $12,000. Major insurers including Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare cover TMS for patients who meet treatment resistant criteria. FDA approved esketamine (Spravato) also has insurance coverage pathways, while IV ketamine infusions, running $400 to $800 per session, are rarely covered.
In the United Kingdom, the NHS covers TMS in select cases, and esketamine is available through NICE approved pathways for TRD.
In Canada, some provincial health plans and private insurers cover TMS partially. Ketamine coverage remains limited but is growing.
In Australia, TMS is covered under some private health insurance plans, and TGA approved esketamine has limited PBS coverage.
In Pakistan and most developing countries, neither TMS nor ketamine therapy currently has insurance coverage. Both treatments are fully out of pocket, which places them out of reach for many patients. This is a real and significant healthcare gap that deserves honest acknowledgment. If you are in this situation, speak directly with a psychiatric center about payment plans or clinical trial opportunities, as some research programs offer these treatments at reduced or no cost.
So Which One Is Right for You?
That depends on your clinical history, how urgent your symptoms are, your location, and your tolerance for different side effects.
If you need relief fast, especially if suicidal thoughts are part of the picture, ketamine or esketamine may be the more appropriate starting point, under proper medical supervision.
If you are looking for a well-tolerated option with durable long-term results and minimal systemic effects, TMS is often the first recommendation from psychiatrists for treatment resistant depression.
In some cases, both can be combined or used sequentially. Mental health treatment is rarely one size fits all.
What matters most is that you don’t stop advocating for yourself. Treatment resistant doesn’t mean treatment impossible. Talk to a psychiatrist who specializes in TRD, and now you have the vocabulary to ask the right questions.
FAQs
Q1. Can I try TMS or ketamine if I am still on antidepressants?
Yes, in most cases. Many patients continue their current medications during TMS treatment. Ketamine combinations require more careful evaluation by your doctor, but it is not automatically ruled out. Always disclose everything you are taking before starting either treatment.
Q2. How many ketamine infusions do I need before seeing results?
Most patients notice a difference after the first or second infusion. The standard initial course is six infusions over two to three weeks. Some people respond after one session, others need the full course. Maintenance infusions afterward depend on how long your relief lasts.
Q3. Is TMS painful?
Not painful for most people. You may feel a tapping or knocking sensation on your scalp during the session. Mild headaches are common in the first few sessions and usually stop as your body adjusts.
Q4. Is ketamine therapy the same as recreational ketamine abuse?
No, Medical ketamine therapy uses precisely controlled low doses in a supervised clinical setting with monitoring. Recreational misuse involves uncontrolled doses with no medical oversight. The context, dose, and purpose are completely different.
Q5. How do I know if I qualify for these treatments?
The standard qualification is failing at least two antidepressant medications at adequate doses and duration. A psychiatrist will review your full history and determine eligibility. Some insurance providers in the US, UK, Canada, and Australia also have their own additional criteria for coverage approval.
Q6. Are these treatments available in Pakistan or other developing countries?
TMS machines are available in some private psychiatric hospitals in Pakistan’s major cities including Karachi, Lahore, and Islamabad, but costs are fully out of pocket. Ketamine infusions for depression are less widely available. Ask your psychiatrist directly about availability in your city.
Call to Action
If you or someone you love has been struggling with depression that simply will not respond to medication, please do not give up. TMS and ketamine therapy have genuinely changed lives for people who felt completely out of options.
Your next step is simple, book a consultation with a psychiatrist who specializes in treatment resistant depression and ask them directly whether TMS or ketamine therapy is appropriate for your situation. Come prepared with your medication history, how long you tried each one, and the doses you were on. That information helps your doctor move faster and make a better decision for you.
You deserve treatment that actually works. Go find it.
Disclaimer
This article is written for general informational and educational purposes only. It does not constitute medical advice, diagnosis, or a treatment recommendation. TMS and ketamine therapy are medical procedures that must be evaluated, prescribed, and supervised by a licensed healthcare professional.
Individual results vary. Treatment eligibility, costs, insurance coverage, and availability differ by country, region, and individual clinical history. Always consult a qualified psychiatrist or medical professional before making any decisions about your mental health treatment.
References
• George MS, et al. “Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder.” Archives of General Psychiatry. 2010.
• Berlim MT, et al. “Response, remission and dropout rates following high frequency repetitive TMS for treating major depression.” Psychological Medicine. 2014.
• Zarate CA, et al. “A randomized trial of an N-methyl-D-aspartate antagonist in treatment resistant major depression.” Archives of General Psychiatry. 2006.
• Murrough JW, et al. “Antidepressant efficacy of ketamine in treatment resistant major depression.” American Journal of Psychiatry. 2013.
• US Food and Drug Administration. “FDA clears transcranial magnetic stimulation device for OCD and MDD.” FDA.gov. 2008 and 2020.
• National Institute for Health and Care Excellence (NICE). “Esketamine for treatment resistant depression.” NICE Guidelines. UK. 2022.
• Therapeutic Goods Administration (TGA). “Esketamine nasal spray product information.” TGA.gov.au. Australia.
• Canadian Psychiatric Association. “Clinical practice guidelines for the treatment of depressive disorders.” Canadian Journal of Psychiatry. 2016.
